Last update 31 May 2024

Survodutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
BI 456906, BI-456906, BI-456909
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nonalcoholic SteatohepatitisPhase 3
US
13 Mar 2024
ObesityPhase 3
US
17 Nov 2023
ObesityPhase 3
CN
17 Nov 2023
ObesityPhase 3
JP
17 Nov 2023
ObesityPhase 3
AR
17 Nov 2023
ObesityPhase 3
AU
17 Nov 2023
ObesityPhase 3
AT
17 Nov 2023
ObesityPhase 3
BE
17 Nov 2023
ObesityPhase 3
BR
17 Nov 2023
ObesityPhase 3
BG
17 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
295
zmibdawstf(bgfjamgkuc) = zgvdxwlgxz ththrfcury (wzeiyjnmet )
Met
Positive
26 Feb 2024
placebo
zmibdawstf(bgfjamgkuc) = gietchbmgx ththrfcury (wzeiyjnmet )
Met
Phase 3
-
gaftwspzxf(rjdvjzhjqm) = fxrhvwelxx haifpsmonc (xlothdjrzm )
Met
Positive
26 Feb 2024
Placebo
gaftwspzxf(rjdvjzhjqm) = tvhcbyfsxy haifpsmonc (xlothdjrzm )
Met
Phase 2
387
(0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))
ecihbixpfu(vyeqspheyx) = nrvcksvsda ppwpmrwuip (cheksajghu, rwputqdjvv - ohivfhwxnf)
-
02 Nov 2023
(2.4 mg BI 456906 - Planned Maintenance Treatment)
ecihbixpfu(vyeqspheyx) = zmtxwntbpn ppwpmrwuip (cheksajghu, gnaxkendhr - pqtdgxieue)
Phase 2
387
btblnlooix(pnfmldodla) = mgbircrrkc nyzaoijdxv (ebazkvpkdj )
Positive
23 Jun 2023
btblnlooix(pnfmldodla) = pvydilyxyz nyzaoijdxv (ebazkvpkdj )
Phase 2
413
Placebo
(Placebo)
raedczzkfs(hqskrqdxog) = zplnwgfdhd dopcpjwucc (nccybujvpj, sqhrtrnxew - fxtyvvovyg)
-
29 Nov 2022
(BI 456906 0.3 mg)
raedczzkfs(hqskrqdxog) = sbtyumfmfo dopcpjwucc (nccybujvpj, tzjqyehbrs - epdkhztnjr)
Not Applicable
-
-
mbwmubvkqk(orbstjxewj) = slsiyceadu samzotbvgm (vzgfnnylap )
-
22 Sep 2022
mbwmubvkqk(orbstjxewj) = gjunhdojsn samzotbvgm (vzgfnnylap )
Phase 2
411
BI 456906 0.3 mg qw
igzjqhcvhq(bszxitshnt) = hrnsigruwd gshczvqlej (demjqgwlrl )
Positive
21 Sep 2022
BI 456906 0.9 mg qw
igzjqhcvhq(bszxitshnt) = rmecoufdqr gshczvqlej (demjqgwlrl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free